3Sylaja PN, Demchuk AM. Intravenous thrombolytic therapy in acute ischemic stroke: the art and science of treatment decision making. Ann Indian Acad Neurol, 2008, 11 (5): 24-29.
4Lansberg MG, Thijs VN, Bammer R, et al; DEFUSE Investigators. Risk factors of symptomatic intracerebral hemorrhage after tPA therapy for acute stroke. Stroke, 2007, 38: 2275-2278.
5Baumann CR, Baumgartner RW, Gandjour J, et al. Good outcomes in ischemic stroke patients treated with intravenous thrombolysis despite regressing neurological symptoms. Stroke, 2006, 37: 1332- 1333.
6Sylaja PN, Dong W, Grotta JC, et al. Safety outcomes of Alteplase among acute ischemic stroke patients with special characteristics. Neurocrit Care, 2007, 6:181-185.
7Sylaja PN, Cote R, Buchan AM, et al; Canadian Alteplase for Stroke Effectiveness Study (CASES) Investigators. Thrombolysis in patients older than 80 years with acute ischaemic stroke: Canadian Alteplase for Stroke Effectiveness Study. J Neurol Neurosurg Psychiatry, 2006, 77: 826-829.
8Hsu YC, Sung SF, Ong CT, et al. Intravenous thromholytic therapy for acute ischemic stroke: the experience of a community hospital. Acta Neurol Taiwan, 2009, 18: 14-20.
9Engelter ST, Bonati LH, Lyrer PA. Intravenous thrombolysis in stroke patients of ≥ 80 verstts < 80 years of age-a systematic review across cohort studies. Age Ageing, 2006, 35:572-580.
10Toni D, Lorenzano S, Agnelli G, et al. Intravenous thrombolysis with rt-PA in acute ischemic stroke patients aged older than 80 years in Italy. Cerebrovasc Dis, 2008, 25: 129-135.
